Getting a hydrophilic, charged molecule past intact stratum corneum is the central challenge in topical peptide formulation, and concentration is rarely the limiting factor.
Key Takeaways
- The stratum corneum presents a lipid-rich, hydrophobic environment that excludes hydrophilic and charged species.
- Microneedles, iontophoresis, and sonophoresis bypass or disrupt the barrier mechanically or electrically.
- Topical peptides with meaningful clinical support are few, and most evidence is cosmetic-endpoint rather than structural.
Why skin is a difficult barrier
The stratum corneum presents a lipid-rich, hydrophobic environment that excludes hydrophilic and charged species. Peptides are typically both, which is why passive flux across intact skin is low for most sequences without assistance.
Vehicle and enhancer strategies
Chemical penetration enhancers, liposomal and ethosomal carriers, and microemulsions are the main approaches. Each increases delivery by different mechanisms, and the choice depends on the peptide’s charge and size as much as on the vehicle.
For related mechanism work, see peptide storage stability.
Physical enhancement methods
Microneedles, iontophoresis, and sonophoresis bypass or disrupt the barrier mechanically or electrically. They are considerably more effective than passive formulation but move the product out of a simple cosmetic claim and into a device category.
Stability in the finished vehicle
The peptide must survive the vehicle, which means checking pH compatibility, avoiding chelators for metallopeptides, and confirming that emulsifiers do not strip an active complex. Stability should be tested in the finished product, not only in the stock solution.
Setting realistic claims
Topical peptides with meaningful clinical support are few, and most evidence is cosmetic-endpoint rather than structural. Claims should be tied to what was actually measured in the finished formulation rather than to the ingredient literature.
Experimental Conditions and Practical Setup
Permeation is measured on excised skin or a validated substitute in a diffusion cell, with receptor fluid sampled at intervals and the peptide quantified by LC-MS. The receptor fluid is chosen so that the peptide remains soluble in it, since poor sink conditions underestimate permeation and are a common source of misleadingly low results.
Enhancement approaches and their trade-offs
| Approach | Mechanism | Trade-off |
|---|---|---|
| Chemical enhancers | Disrupt lipid packing | Tolerability |
| Liposomal or ethosomal carriers | Improve partitioning | Loading and stability |
| Cyclodextrin complexation | Raise apparent solubility | Peptide-specific benefit |
| Microneedles | Bypass the barrier | Device regulation, sterility |
Practical Notes for the Bench
- Test stability in the finished vehicle, not just the stock solution.
- Avoid chelating excipients when formulating metallopeptides.
- Tie claims to finished-formulation data rather than ingredient studies.
Frequently Asked Questions
Why does simply raising the concentration not work?
Because the barrier excludes the molecule on the basis of charge and hydrophilicity, so flux is limited by permeability rather than by the concentration gradient.
Do liposomal carriers help?
They can improve deposition, but the effect is sequence-dependent and should be demonstrated for each peptide and vehicle combination.
Is microneedling a formulation or a device?
It is a physical enhancement method that generally moves the product into a device-regulated category.
Is increasing concentration a viable strategy?
Usually not. Flux is limited by permeability rather than by the concentration gradient, so raising concentration rarely produces a proportional increase in delivery.
Related Reading
- peptide storage stability
- nasal peptide delivery
- peptide sterility testing
- thymosin alpha-1
- BPC-157 mechanism of action
References & Further Reading
- Wei Q et al. A skin-permeable polymer for non-invasive transdermal insulin delivery. Nature. 2025. PubMed 41261125
- Kirkby M et al. Microneedle Mediated Transdermal Delivery of Protein, Peptide and Antibody Based Therapeutics: Current Status and Future Considerations. Pharm Res. 2020. PubMed 32488611
- Bodde HE et al. Transdermal peptide delivery. Biochem Soc Trans. 1989. PubMed 2533571
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- Peptide research collection at Nature
Educational content for research staff. Nothing here should be read as advice on human or veterinary use of any compound.
Reviewed by Dr. Aiko Tanaka, Bioactive Peptides & Dermatological Research.